Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:
Quantum BioPharma secured FDA clearance to proceed with a Phase 2 clinical trial of Lucid-MS for progressive multiple sclerosis, validating its IND application for this first-in-class neuroprotective therapy. The randomized, double-blind, placebo-controlled study targets the underlying mechanism of demyelination, addressing a market projected to reach $38.62 billion globally by 2030.
Key figures
- Drug Name
- Lucid-MS (Lucid-21-302)
- Phase Of Trial
- Phase 2
- Unbuzzd ownership
- 19.84%
- Cash liquid assets
- >$10 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.